Contact Info

Oops! Something went wrong while submitting the form.

Ricardo Campello

Partner

No items found.

Ricardo Campello is a partner at Licks Attorneys, based in our Rio de Janeiro office. Since the firm was founded, at the time as a junior associate, Mr. Campello has focused his practice on relevant matters for pharmaceutical, biotech, cannabis, medical device, and cosmetics companies. His wide-ranging practice includes assisting clients in their day-to-day business operations, but also handling complex time-sensitive litigations and consulting projects in the context of clinical trials review process and sponsor’s responsibilities; application for marketing approval and post-marketing amendments before Anvisa; pricing before the Chamber of Drug Market Regulation (CMED); product liability; M&A transactions; general commercial and contractual matters; and investigations of Anticorruption practices and food and drug violations. Aside his regulatory practice, Mr. Campello also works on the Government Procurement arena, having helped clients to win and challenge successfully bids and single source-type acquisitions. He has been deeply involved with the implementation of the Productive Development Partnerships (PDP) Program, a Federal Government’s Industrial Policy for the pharmaceutical and biotech sector. More than once, Mr. Campello has helped clients to submit proposals and to put in place PDP agreements with Government-owned pharmaceutical industries for small molecules and biologics.

+ Languages
  • Portuguese
  • English
+ Practice Areas
  • Litigation
  • Government Affairs & International Relations
  • Regulatory
  • Patents
  • Antitrust & Competition
  • Corporate & Transactions
+ Representative Cases
  • Represented a US biopharmaceutical company in 2015 on the first class action in Brazil discussing whether the sponsor of a clinical trial is bound to supply, without any time limitation, the drug tested in the clinical trials to an individual after their completion, as well as whether the sponsor is liable to reimburse the government for the costs involving said supply;
  • Assisted a Korean pharmaceutical company on all steps of the negotiations of the 2015 round of the PDP program before the Ministry of Health;
  • Represented in 2017 a Japanese pharmaceutical company in the leading case discussing the renewal of a PDP agreement between a Brazilian company and a government-owned pharmaceutical industry, having obtained a preliminary injunction, later confirmed on the merits, preventing the illegal renewal;
  • Represented in 2021 a Brazilian pharmaceutical company in multiple lawsuits filed by private and public hospitals nationwide seeking expedited delivery of emergency intubation drugs during the Covid-19 pandemic, preventing the company from being compelled to provide the requested drugs within an unreasonable deadline.  
  • Represented in 2021 a Brazilian pharmaceutical company in a leading case on the judicial review of a Brazilian Anticorruption Act-based procedure initiated by the Brazilian Food and Drug Agency in the context of a drug approval process, obtaining a preliminary injunction to stay the administrative procedure and securing its entire annulment, preventing the client from paying a BRL 20 million fine.
  • Represented in 2021 a Brazilian pharmaceutical company in a leading case discussing the adjustment of price caps of drugs set by the Brazilian drug pricing regulator called CMED, obtaining a court order authorizing the price adjustment in 90% higher of the cap of one of the company’s biologicals.
  • Assisted in 2021 and following years a Brazilian pharmaceutical company with the acquisition of assets from another Brazilian company that was under judicial reorganization, including a thorough due diligence and, after the acquisition, development of strategy to protect the client from undue attempts by creditors that could affect the acquired assets.
  • Represented in 2021 a Brazilian pharmaceutical company in a lawsuit against the Ministry of Health seeking to prevent it from procuring without a competitive bidding approx. BRL 200 million of a drug for the treatment of cancer, having obtained an injunction later confirmed on the merits that stayed the illegal acquisition, allowing the client to participate and win bids that followed.
  • Represented in 2022 a Brazilian pharmaceutical company in an administrative procedure initiated by the Brazilian Food and Drug Agency regarding the recall of a drug for hospital use, preventing the client from being required to issue a public safety alert, as the company had already notified its entire distribution chain of the recall, and from damage on its reputation.
  • Represented in 2022 a Brazilian pharmaceutical company in a leading case regarding violations of due process-related rights under a Brazilian Anticorruption Act-based sanctioning procedure initiated by the Brazilian Revenue Service (RFB), obtaining a preliminary injunction to stay the administrative procedure until the RFB discloses evidence upon which its allegations are based.
  • Assisted in 2023 a Brazilian pharmaceutical company with the acquisition of a Brazilian subsidiary of a foreign pharmaceutical group that was under judicial reorganization, having conducted all due diligences and consulted during the legal strategy definition
  • Represented in 2023 a Brazilian pharmaceutical company in the first lawsuit seeking to enforce a private company's right to supply its drug under the Ministry of Health's PDP program meeting the exact percentage of the SUS's drug needs outlined in the PDP agreement, obtaining a preliminary injunction to suspend a public bidding that the Ministry intended to conduct violating the client's right.
  • Represented in 2023 a Brazilian pharmaceutical company in a leading case on the judicial review of a Brazilian Anticorruption Act-based procedure initiated by the Brazilian Office of the Comptroller General (CGU) involving tax incentives obtained by the client through cultural projects under the so-called “Rouanet Act”. The Court of Appeals overturned the trial judge’s decision, recognizing that the Anticorruption Act does not apply to tax-related matters and granting the preliminary injunction request to stay the procedure.
  • Represented in 2024 a Brazilian pharmaceutical company in a leading case in the sense of applying to outsourcing of manufacturing pharmaceutical products the Brazilian Civil Code's requirement for a reasonable termination notice period. After obtaining a preliminary injunction to compel the contracted company to continue manufacturing the remaining batches scheduled for that year despite of its decision to terminate the agreement, the parties reached a settlement that allowed the client to maintain its product on the market while transitioning to in-house production, preventing a loss of 10% in its annual revenue.
+ Professional Highlights
  • Legal 500 – Life Sciences (2025, 2022);
  • Leaders League – Life Sciences (2024);
  • Leaders League – Civil and Commercial Litigation (2024);
  • Análise Advocacia - Pharmaceutical (2023, 2022, 2021);
  • Análise Advocacia - Rio de Janeiro (2022);
+ Representative Experience
+ Affiliations
  • Brazilian Bar Association – Rio de Janeiro and Sao Paulo Sections (OAB/RJ and OAB/SP).
+ Education
  • LL.M, Government Procurement, George Washington University (GWU), 2020;
  • LL.M, Public Law and Regulation, Getulio Vargas Foundation (FGV), 2012;
  • LL.B, Federal University of Rio de Janeiro (UFRJ), 2009;
+ Publications
+ Speaking Engagements and Others
+ Articles